TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06201455

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEI+GT
Description: After a standard phacoemulsification with intraocular lens implantation (PEI) is performed. The viscoelastic substance will be injected into the anterior chamber again to maintain corneal rigidity. The surgical microscope will be adjusted to tilt 35-40° towards the patient's nasal side, and the patient's head position will be adjusted to tilt 35-40° accordingly. A viscoelastic substance will be applied to the corneal surface to facilitate direct visualization of the angle structures under a gonioscope. The Tanito Microhook will be inserted through the main incision into the anterior chamber, and under gonioscopic guidance, the nasal (or inferonasal) trabecular meshwork and the inner wall of Schlemm's canal will be incised, approximately 120° in extent (60° in each direction).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEI+MED
Description: Participants assigned to control group will undergo routine PEI surgery. Postoperatively, the decision to administer anti-glaucoma medication is based on intraocular pressure (IOP) measurements, and the target IOP is set at 16 mmHg. The selection of medications is informed by the Asia Pacific Glaucoma Guidelines (Kugler Publications, 2016), while the target IOP reference is the European Glaucoma Guidelines.
Study: NCT05217511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: NMES was performed using a portable machine.The negative electrodes were placed in the motor points of the following muscles: chest muscles (pectoralis major muscle fibres) and rectus abdominis muscles bilaterally. A second (positive) electrode was positioned distally to the first, at a site close to the muscle that was being electrically stimulated, totalling 1 channel with 2 electrodes for each muscle . Each NMES session lasted 30 min. The following parameters were used: 50 Hz frequency, pulse duration 300 ms, rise time 1 s, stimulus time (ON) 3 s, decay time 1 s, and relaxation time (OFF) 10 s. Intensity was increased until muscle contraction was visible or could be identified through palpation. In conscious patients, intensity was adjusted according to their tolerance.
Study: NCT04756128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg
Description: Colchicine is an oral anti-inflammatory agent that is relatively inexpensive, readily available, and has been used for generations. Approved for treatment and prophylaxis of gout flares and Mediterranean fever, it is also used in a variety of other inflammatory conditions (e.g. pericarditis and diffuse vascular inflammation such as Behcet syndrome). Colchicine binds to tubulin causing depolymerization, which interferes with neutrophil chemotaxis, adhesion, and mobilization to sites of inflammation, and contributes to reduction in superoxide production; through interference of the NLRP3 inflammasome protein complex, colchicine inhibits IL-1b, IL-6, and IL-18 production.~For this study, patients enrolled in a colchicine containing arm will receive 0.6mg of colchicine BID (unless renal function/gastrointestinal issues require adjustments described in the protocol)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg
Description: Colchicine is an oral anti-inflammatory agent that is relatively inexpensive, readily available, and has been used for generations. Approved for treatment and prophylaxis of gout flares and Mediterranean fever, it is also used in a variety of other inflammatory conditions (e.g. pericarditis and diffuse vascular inflammation such as Behcet syndrome). Colchicine binds to tubulin causing depolymerization, which interferes with neutrophil chemotaxis, adhesion, and mobilization to sites of inflammation, and contributes to reduction in superoxide production; through interference of the NLRP3 inflammasome protein complex, colchicine inhibits IL-1b, IL-6, and IL-18 production.~For this study, patients enrolled in a colchicine containing arm will receive 0.6mg of colchicine BID (unless renal function/gastrointestinal issues require adjustments described in the protocol)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Most well known as an opioid antagonist, or a treatment for alcohol dependence, naltrexone also possesses immunomodulatory effects. Seen exclusively at low doses, this attribute is being employed in the pain community as a novel anti-inflammatory agent that has been shown to reduce symptom severity in fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome.~For this study, patients enrolled in a naltrexone-containing arm will take their daily dose of the medication (4.5mg) by oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Most well known as an opioid antagonist, or a treatment for alcohol dependence, naltrexone also possesses immunomodulatory effects. Seen exclusively at low doses, this attribute is being employed in the pain community as a novel anti-inflammatory agent that has been shown to reduce symptom severity in fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome.~For this study, patients enrolled in a naltrexone-containing arm will take their daily dose of the medication (4.5mg) by oral suspension.
Study: NCT05447676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalfampridine
Description: The study drug (4-AP) will be administered as a 10 mg dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalfampridine
Description: The study drug (4-AP) will be administered as a 10 mg dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drug
Description: The pharmacy will also provide a placebo drug that looks identical to 4-AP to verify participants and therapists do not know who is receiving the drug and who is receiving the placebo.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STDP stimulation
Description: Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STDP stimulation
Description: Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: STDP stimulation
Description: Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Lower-limb exercises will involve over-ground walking, treadmill, walking and stair climbing training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Lower-limb exercises will involve over-ground walking, treadmill, walking and stair climbing training.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise training
Description: Lower-limb exercises will involve over-ground walking, treadmill, walking and stair climbing training.
Study: NCT06172348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: Ritlecitinib 100 milligrams (mg) will be provided as either solution or capsule formulation (2 capsules of 50 mg)
Study: NCT05299372

Intervention type: OTHER
Group type: OTHER
Intervention: Telemonitoring via Careportal®
Description: The question sets and overnight oximetry results will be monitored and screened by a call centre commissioned by the Liverpool Clinical Commissioning Group (LCCG). The call centre will screen the weekly data and contact clinicians where appropriate (i.e. NIV team, MND specialist nurse, or patient's GP). PVI data will be examined by NIV physiotherapists, where required, following the contact from LCCG to ensure the maximum benefits of NIV to patients.
Study: NCT05302024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Oral iguratimod (25 mg twice daily) for 12 weeks. Iguratimod is a new drug for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), which was filed for marketing in Japan in 2003. It can significantly reduce the inflammatory response, not only selectively inhibit COX-2, but also inhibit the production of inflammatory cytokines, tumor necrosis factor, lymphocytes and immunoglobulins, and has an autoimmunomodulatory effect; it has a rapid onset of action, better efficacy and fewer adverse effects than existing drugs, and is effective in patients for whom other drugs are ineffective. It has been reported in the literature that in vitro iguratimod can inhibit the activity of nuclear factor-κB (NF-κB), which in turn inhibits the production of inflammatory cytokines (interleukin-1, interleukin-6, interleukin-8, tumor necrosis factor alpha). Iguratimod also interacts directly with mouse and human B cells in vitro to inhibit the production of immunoglobulins.
Study: NCT06389929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: In line with the skill they will determine for one of the applications in the Skill Checklists (Breastfeeding Education Skill Control Form, Breast Care and Giving Care to Mothers with Breast Engorgement Skill Control Form, Breast Self-Examination (KKMM) Training Skill Control Form) apply.
Study: NCT06478732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health services
Description: Implement comprehensive heart failure management for patients in the experimental group using the HeartMed-HF digital therapy
Study: NCT04758546

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Screening criteria for weaning and minimal ventilatory settings for spontaneous breathing trial
Description: Aggressive screening criteria: Walsh Conservative screening criteria: Boles High minimal ventilatory settings: pressure Support 8 + positive end-expiratory pressure 5 Low minimal ventilatory settings: pressure support 5

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Screening criteria for weaning and minimal ventilatory settings for spontaneous breathing trial
Description: Aggressive screening criteria: Walsh Conservative screening criteria: Boles High minimal ventilatory settings: pressure Support 8 + positive end-expiratory pressure 5 Low minimal ventilatory settings: pressure support 5

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Screening criteria for weaning and minimal ventilatory settings for spontaneous breathing trial
Description: Aggressive screening criteria: Walsh Conservative screening criteria: Boles High minimal ventilatory settings: pressure Support 8 + positive end-expiratory pressure 5 Low minimal ventilatory settings: pressure support 5

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Screening criteria for weaning and minimal ventilatory settings for spontaneous breathing trial
Description: Aggressive screening criteria: Walsh Conservative screening criteria: Boles High minimal ventilatory settings: pressure Support 8 + positive end-expiratory pressure 5 Low minimal ventilatory settings: pressure support 5
Study: NCT05270473

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uterine compressive sutures
Description: uterine compression sutures comaprison

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uterine compressive sutures
Description: uterine compression sutures comaprison
Study: NCT04514692

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Description: Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Description: Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Description: Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Description: Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCSF
Description: Granulocyte Colony Stimulating Factor (GCSF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCSF
Description: Granulocyte Colony Stimulating Factor (GCSF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCSF
Description: Granulocyte Colony Stimulating Factor (GCSF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCSF
Description: Granulocyte Colony Stimulating Factor (GCSF)
Study: NCT05188313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Intravenous administration of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Intravenous administration of study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Intravenous administration of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous administration of study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Intravenous administration of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous administration of study drug
Study: NCT05644535

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebrospinal fluid densitometry
Description: After obtaining the patient's cerebrospinal fluid specimen, the actual mass of the cerebrospinal fluid was measured by pipetting 1000 μL of cerebrospinal fluid specimen on an analytical balance using a pipette gun, and all specimens were measured three times and the average of the three times was taken as the final mass of 1000 μL of that specimen. After the mass measurement, the residual cerebrospinal fluid was disposed of as medical waste. The density of each specimen was obtained according to the density to mass conversion formula ρ=m/v.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebrospinal fluid densitometry
Description: After obtaining the patient's cerebrospinal fluid specimen, the actual mass of the cerebrospinal fluid was measured by pipetting 1000 μL of cerebrospinal fluid specimen on an analytical balance using a pipette gun, and all specimens were measured three times and the average of the three times was taken as the final mass of 1000 μL of that specimen. After the mass measurement, the residual cerebrospinal fluid was disposed of as medical waste. The density of each specimen was obtained according to the density to mass conversion formula ρ=m/v.
Study: NCT05468749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Single 12 mg oral dose administered on Day 1
Study: NCT05247892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided S1 Radiofrequency stimulation
Description: Pulsed radiofrequency stimulation of the S1 dorsal root ganglia under ultrasound-guidance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopic-guided S1 Radiofrequency stimulation
Description: Pulsed radiofrequency stimulation of the S1 dorsal root ganglia under fluoroscopy-guidance
Study: NCT05500482

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhoid conjugate Vaccine
Description: TyphiBEV is a clear colourless monovalent vaccine containing 25 µg of Typhoid Vi polysaccharide manufactured using the Citrobacter freundii sensu lato3056 (Vi) and is conjugated to CRM 197 as a carrier protein. Sodium chloride and Phosphate buffer are used as a buffering agent in the vaccine formulation with 2-Phenoxyethanol as a preservative.
Study: NCT05644535

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebrospinal fluid densitometry
Description: After obtaining the patient's cerebrospinal fluid specimen, the actual mass of the cerebrospinal fluid was measured by pipetting 1000 μL of cerebrospinal fluid specimen on an analytical balance using a pipette gun, and all specimens were measured three times and the average of the three times was taken as the final mass of 1000 μL of that specimen. After the mass measurement, the residual cerebrospinal fluid was disposed of as medical waste. The density of each specimen was obtained according to the density to mass conversion formula ρ=m/v.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebrospinal fluid densitometry
Description: After obtaining the patient's cerebrospinal fluid specimen, the actual mass of the cerebrospinal fluid was measured by pipetting 1000 μL of cerebrospinal fluid specimen on an analytical balance using a pipette gun, and all specimens were measured three times and the average of the three times was taken as the final mass of 1000 μL of that specimen. After the mass measurement, the residual cerebrospinal fluid was disposed of as medical waste. The density of each specimen was obtained according to the density to mass conversion formula ρ=m/v.

Intervention type: DIAGNOSTIC_TEST
Intervention: blood routine examination
Description: After obtaining the patient's blood specimens, they were sent to the laboratory for blood routine examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: blood routine examination
Description: After obtaining the patient's blood specimens, they were sent to the laboratory for blood routine examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: blood routine examination
Description: After obtaining the patient's blood specimens, they were sent to the laboratory for blood routine examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: blood routine examination
Description: After obtaining the patient's blood specimens, they were sent to the laboratory for blood routine examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood electrolyte examination
Description: After obtaining the patient's blood specimens, they were sent to the laboratory for blood electrolyte examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood electrolyte examination
Description: After obtaining the patient's blood specimens, they were sent to the laboratory for blood electrolyte examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood electrolyte examination
Description: After obtaining the patient's blood specimens, they were sent to the laboratory for blood electrolyte examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood electrolyte examination
Description: After obtaining the patient's blood specimens, they were sent to the laboratory for blood electrolyte examination.
Study: NCT05434715

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thyroidectomy
Description: removal of the thyroid gland

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thyroidectomy
Description: removal of the thyroid gland
Study: NCT06222034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Film-coated mini-tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Commercially developed film-coated tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Commercially developed film-coated tablet administered orally once daily
Study: NCT06153901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoloop mediated cardioplication (ECLC) procedure
Description: The ECLC surgery first incises the mucosa and submucosa on the small curvature side and posterior side (approximately 3/4 of the total circumference) of the diaphragm level cardia until smooth muscle fibers are exposed; Fix the metal clip covered with nylon rope on the exposed smooth muscle layer, and finally tighten the nylon rope to achieve full folding of the cardia. After the surgery, the patient fasted overnight and received intravenous PPI treatment. On the second day after surgery, a fluid diet was restored and discharge was possible. ECLC is simple, easy to operate, relatively inexpensive, and minimally invasive, and is expected to become a new method for treating severe gastroesophageal reflux disease.
Study: NCT06647251

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Q-MODE : radiofrequency ablation up to 50W
Description: The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE option: the intensity of radiofrequency to isolate the pulmonary vein is limited to 50W.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Q-MODE+ : radiofrequency up to 90W
Description: The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE+ option: the intensity of radiofrequency to isolate the pulmonary vein is limited to 90W.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybride Q-MODE/Q-MODE+: radiofrequency ablation up to 50W in the anterior part, and 90W in the posterior part
Description: The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE/Q-MODE+ option: the intensity of radiofrequency delivered to isolate the pulmonary vein is limited to 50W in the anterior part and to 90W in the posterior part.
Study: NCT04612699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally